Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Invanz
Ertapenem is a broad-spectrum, long-acting, once-daily parenteral carbapenem antibiotic indicated for the treatment of moderate to severe infections caused by susceptible bacteria. It belongs to the beta-lactam class of antibiotics, which work by inhibiting bacterial cell wall synthesis. Ertapenem exhibits activity against a wide range of Gram-positive and Gram-negative bacteria, including many common pathogens responsible for intra-abdominal infections, complicated urinary tract infections, acute pelvic infections, community-acquired pneumonia, and skin and skin structure infections.
Treatment of moderate to severe infections, including intra-abdominal, urinary tract, pelvic, pneumonia, and skin infections.
Outcome:
Increased ertapenem levels
Mechanism:
Reduces renal excretion
Outcome:
Increased INR/bleeding risk
Mechanism:
May affect vitamin K-dependent clotting factors
Outcome:
Reduced ertapenem absorption
Mechanism:
Chelation/binding
Most likely new formulation: Extended-release injectable formulation (Year 2026, 60% confidence)
Based on current usage trends and emerging resistance patterns, there is a 70% likelihood of new guidelines for ertapenem use within the next 5 years.
Carbapenem, Beta-lactam Antibiotic
Carbapenem